Abstract:Somatic epidermal growth factor receptor (EGFR) mutations are now routinely integrated in the molecular diagnosis of non-small cell lung cancers (NSCLC). Next generation sequencing with paired blood and tumor tissue enable the simultaneous detecting of germline and somatic EGFR mutations. However, the impact of EGFR germline mutations on response to EGFR tyrosine kinase inhibitors (TKIs) is not well known [ 1 Centeno I. Blay P. Santamaria I. Astudillo A. Pitiot A.S. Osorio F.G. Gonzalez-Arriaga P. Iglesias F. Menendez P. Tardon A. Freije J.M. Balbin M. Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma. BMC Cancer. 2011; 11: 172 Crossref PubMed Scopus (24) Google Scholar , 2 Prim N. Legrain M. Guerin E. Mennecier B. Weingertner N. Voegeli A.-C. Guenot D. Maugard C.M. Quoix A.-E. Beau-Faller M. Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients. Eur. Respir. Rev. 2014; 23: 390-392 Crossref PubMed Scopus (17) Google Scholar , 3 Song H. Chen Y. Yan Z. Sun G. Shi Z. Response to Osimertinib in a NSCLC Patient Harboring EGFR V843I Germ-Line Mutation. Lung Cancer. 2020; 150: 247-248 Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar ]. We report here six patients with concurrent somatic and germline EGFR variants identified with a penal of 1021 cancer-related genes (∼1.4 Mbp) using Gene + Seq 2000 instrument (Geneplus-Beijing, China). These patients demonstrated diverse responses to EGFR-TKI (Table 1). To the date of cutoff, 4 of the 6 patients had passed away, with a medium overall survival (OS) of 15 months (range, 8-NR) (Table 1), the medium progress free survival (PFS) of EGFR-TKI 4 months (range, 1–16 months), which was much shorter than patients without germline EGFR mutation. Table 1Patient characteristics, response to EGFR-TKI and EGFR germline and somatic mutations. Patient ID Gender Age at diagnosis Family history Smoking EGFR-TKI PFS OS EGFR germline EGFR somatic in cis / in trans Other somatic mutations EG001 Female 53 No No Gefitinib 8 31 R836C L747_A750delinsP NA 1 EG002 Male 59 No Yes Gefitinib 1 8 D1014N L858R, NA 3, PIK3CA:p.H1047R, CDK12 p.E1327K, CDKN1A p.E56* EG003 Female 44 Elder brother, sister, lung adenocarcinoma No Gefitinib 4 NR T790M G719A,L861Q NA 1 EG004 Female 61 Mother, lung adenocarcinoma No Gefitinib 4 22 V769M L858R NA 11, CDK4 CNV, MDM2 CNV, CCND1 CNV, GAB2 CNV, ABL1 p.S19L, C11orf30 c.71-2A > G, DNMT3A p.G381E, EGFR p.A24S,POM121L12 p.R207S, RPL36A p.R76H, SMARCA4 p.R726H EG005 Male 72 Elder brother, liver carcinoma; elder sister, breast cancer; younger brother, lung adenocarcinoma Yes Icotinib 2 8 P848L L858R in cis 11, ABCC11 p.S294F, CSF1R p.E456*, FAT2 p.S635R, FMN2 p.A952G, FOXA1 p.E383K, NF1 c.61-2A > G, NF1 p.*2819Wfs*?, NTRK1 p.T653S, NTRK3 p.D405Y,RICTOR p.V215E, TP53 p.Q100Rfs*23 EG006 Male 55 No Yes Gefitinib 16 NR K757R E746_A750del in trans 0 Open table in a new tab

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

KRAS Mutation Subtypes Responded Differently to Combination Immunotherapy Via Disturbing Myeloid-Derived Suppressor Cells in Non-Small Cell Lung Cancer.

Brief Report: The Immune Profiles of the Molecular Subtypes of EGFR-Mutant Lung Adenocarcinomas in a Large Real-World Cohort

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Application of Immune Checkpoint Inhibitors in EGFR-mutant Non-Small-cell Lung Cancer: from Bed to Bench

Clinical Outcomes of EGFR-TKI Treatment and Genetic Heterogeneity in Lung Adenocarcinoma Patients with EGFR Mutations on Exons 19 and 21

Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target

EGFR-Mutated Squamous Cell Lung Cancer and Its Association with Outcomes.

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors

Treatment of Uncommon EGFR Mutations in Non-Small Cell Lung Cancer: New Evidence and Treatment

Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer

Does EGFR Mutation Type Influence Patient Reported Outcomes in Patients with Advanced EGFR Mutation Positive Non Small Cell Lung Cancer? Analysis of Two Large, Phase III …

Impact of Plasma EGFR Mutation Fractions on Response to First Generation Tyrosine-Kinase Inhibitor in Treatment of Naïve Non-Small Cell Lung Cancer Patients

Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions

Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma

Diverse Responses to EGFR-TKIs in Patients with Concurrent Germline and Somatic EGFR Mutations

PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations